Biomerica Inc. (BMRA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Biomerica Stock Trades 200% Higher After Prostate Screening Test Receives Approval
Biomerica, Inc. BMRA stock is surging with a session volume of 139.2 million as per data from Benzinga Pro.
Biomerica Inc. (BMRA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biomerica Inc. ever had a stock split?
Biomerica Inc. Profile
| Biotechnology Industry | Healthcare Sector | Zackary S. Irani CEO | NASDAQ (CM) Exchange | 09061H406 CUSIP |
| US Country | 64 Employees | - Last Dividend | 21 Apr 2025 Last Split | 3 Jan 2005 IPO Date |
Overview
Biomerica, Inc. is a pioneering force in the biomedical technology arena, focusing on the innovation, patenting, manufacturing, and global distribution of diagnostic and therapeutic products aimed at the advancement of healthcare. The company emphasizes the creation of products for the diagnosis and treatment of various medical conditions and diseases. With a comprehensive approach to detecting health issues ranging from food intolerances to severe medical complications, Biomerica stands out as a vital contributor to global health solutions. Established in 1971, the company has rooted its headquarters in Irvine, California, marking over five decades of commitment to improving medical diagnostics and therapeutics worldwide.
Products and Services
- Diagnostic Test Kits:
- InFoods IBS:
- H. Pylori Diagnostic Test:
- COVID-19 Diagnostic Products:
Biomerica is renowned for its extensive range of diagnostic test kits designed for the analysis of blood, urine, nasal, or fecal specimens. These kits are instrumental in diagnosing a wide array of diseases, food intolerances, and medical complications. They are adept at measuring minute concentrations of bacterial, hormonal, antibodies, antigens, and other substances present in human fluids. The versatility and sensitivity of these kits make them indispensable in various medical settings, including physician offices, over-the-counter drugstores, and hospital/clinical laboratories. Primarily, these products serve to diagnose gastrointestinal diseases, food intolerances, and conduct esoteric tests.
In an innovative leap, Biomerica is in the process of developing the InFoods IBS diagnostic solution. This cutting-edge product is designed to utilize a simple blood sample for identifying patient-specific foods that can alleviate symptoms of irritable bowel syndrome (IBS). This approach underscores a revolutionary step towards personalized dietary management for individuals suffering from IBS, highlighting Biomerica's commitment to tailored healthcare solutions.
The H. Pylori diagnostic test symbolizes another significant stride in Biomerica's quest for advanced diagnostic tools. This test aids in determining whether a patient is infected with the Helicobacter Pylori bacteria, a common cause of peptic ulcers and an increased risk of stomach cancer. Timely detection through this test can lead to appropriate treatment interventions, thereby preventing further complications.
Responding to the global COVID-19 pandemic, Biomerica has expanded its product range to include diagnostics aimed at identifying infections caused by the COVID-19 virus. These development efforts are tailored to meet the urgent need for rapid, accurate testing solutions, reflecting the company's resilience and adaptability in facing public health challenges. Through these products, Biomerica aims to contribute significantly to controlling the pandemic's spread by enabling early detection and isolation of infected individuals.
